Bristi Basu
Bristi Basu
Unknown affiliation
Verified email at
Cited by
Cited by
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang, JW Henshaw, ...
Journal of Clinical Oncology 31 (15_suppl), 2580-2580, 2013
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
Combining antiangiogenics to overcome resistance: rationale and clinical experience
VM Garcia, B Basu, LR Molife, SB Kaye
Clinical Cancer Research 18 (14), 3750-3761, 2012
Whole-genome sequencing coupled to imputation discovers genetic signals for anthropometric traits
I Tachmazidou, D Süveges, JL Min, GRS Ritchie, J Steinberg, K Walter, ...
The American Journal of Human Genetics 100 (6), 865-884, 2017
Targeting the DNA damage response in oncology: past, present and future perspectives
B Basu, TA Yap, LR Molife, JS De Bono
Current opinion in oncology 24 (3), 316-324, 2012
Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin
B Basu, B Sirohi, P Corrie
Endocrine-related cancer 17 (1), R75-R90, 2010
Quantifying normal human brain metabolism using hyperpolarized [1–13C] pyruvate and magnetic resonance imaging
JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, ...
NeuroImage 189, 171-179, 2019
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
N Cook, B Basu, DM Smith, A Gopinathan, J Evans, WP Steward, ...
British journal of cancer 118 (6), 793-801, 2018
A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.
V Moreno Garcia, RD Baird, KJ Shah, B Basu, N Tunariu, M Blanco, ...
Journal of Clinical Oncology 29 (15_suppl), 3021-3021, 2011
Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study
FM Walter, K Mills, SC Mendonça, GA Abel, B Basu, N Carroll, S Ballard, ...
The Lancet Gastroenterology & Hepatology 1 (4), 298-306, 2016
Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience
E Ghorani, HH Wong, C Hewitt, J Calder, P Corrie, B Basu
Oncology 89 (5), 281-287, 2015
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain
B Basu, PC de Sampaio, H Mohammed, M Fogarasi, P Corrie, ...
The international journal of biochemistry & cell biology 44 (2), 393-403, 2012
PARP inhibitors
B Basu, SK Sandhu, JS de Bono
Drugs 72 (12), 1579-1590, 2012
Imaging breast cancer using hyperpolarized carbon-13 MRI
FA Gallagher, R Woitek, MA McLean, AB Gill, RM Garcia, E Provenzano, ...
Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020
Targeting IGF-1R: throwing out the baby with the bathwater?
B Basu, D Olmos, JS De Bono
British journal of cancer 104 (1), 1-3, 2011
First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
U Banerji, EJ Dean, M Gonzalez, AP Greystoke, B Basu, M Krebs, ...
Journal of Clinical Oncology 30 (15_suppl), 3004-3004, 2012
Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies
B Basu, S Biswas, J Wrigley, B Sirohi, P Corrie
Expert review of anticancer therapy 9 (11), 1583-1598, 2009
A phase 2 study of vatalanib in metastatic melanoma patients
N Cook, B Basu, S Biswas, P Kareclas, C Mann, C Palmer, A Thomas, ...
European Journal of Cancer 46 (15), 2671-2673, 2010
The role of angiogenesis inhibitors in the management of melanoma
K Ahmad Zaki, B Basu, P Corrie
Current topics in medicinal chemistry 12 (1), 32-49, 2012
Targeting angiogenesis in melanoma: prospects for the future
PG Corrie, B Basu, K Ahmad Zaki
Therapeutic advances in medical oncology 2 (6), 367-380, 2010
The system can't perform the operation now. Try again later.
Articles 1–20